ClinicalTrials.gg
CompletedNCT04922944Updated Sep 19, 2024

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

An observational study in Covid19 and Vaccine Reaction, sponsored by Huntington Memorial Hospital. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Huntington Memorial Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
167
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
318th of 521
167 · median 300
Started
2021
with 503 others
Observational
521 of 1,860
52 open now
Registered
1,057th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 318th largest by enrollment of the 521 observational ones that give a count, is one of 504 that started in 2021, is one of 521 observational ones, and was the 1,057th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This research study is studying how healthcare worker recipients react after receiving vaccinations for COVID-19. The objective of the study is to evaluate the immune response to COVID-19 vaccination. The immunity will be evaluated over time by measuring serum semi-quantitative SARS-Co-V2 IgG from blood specimens and analyzing vaccine reaction data. SARS-CoV-2 is the name for the virus responsible for COVID-19 infections. IgG, immunoglobulin G, is an antibody found in the blood that protects against bacterial and viral infections. Study subjects will also be asked to report physical reactions they may have experienced related to vaccinations.

Read the detailed description

As some of the first recipients of SARS-CoV-2 vaccines under emergency authorization use, healthcare workers represent a diverse subpopulation, that are now moving through the immune response to the Pfizer and Moderna mRNA vaccines. As individual responses may vary, this provides an opportunity to evaluate levels of IgG response in relation to age, gender, comorbidities and other factors that may influence immunity. We recognize that, though this is only part of the immune response that may be protective for severe COVID-19 disease, it is a first step in understanding the level and durability of post vaccination SARS-CoV-2 antibodies.

This small, pilot study will evaluate the immune response over time by measuring serum semi-quantitative SARS-CoV-2 IgG from healthcare vaccinees at various timepoints. A high-level review of reactions related to the vaccinations will be performed with the same population of healthcare workers.

03

Conditions studied

  • Covid19
  • Vaccine Reaction

Browse trials for

Keywords

  • SARS-CoV-2
  • vaccination
  • antibody formation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Current employee or active member of the medical staff of Huntington Hospital, Pasadena, CA who has completed the vaccination regimen

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed for study
  • Current employee or active member of the medical staff of Huntington Hospital, Pasadena, CA, (must have valid hospital identification)
  • Must have completed vaccination regimen (two doses if required) no more than 8 weeks ± 5 days before enrollment
  • Must have completed, valid vaccination card, if vaccinations received at a center other than Huntington Hospital
  • Able to read English, sign consent form and complete on-line surveys

Exclusion criteria

Exclusion Criteria:

  • Huntington Hospital employees on leave of absence
  • Anyone not able/willing to provide blood specimens and respond to surveys for the 52-week study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
167 participants (actual)
Patient registry
No

Interventions

  • DrugCOVID-19 vaccine

    Two-dose COVID-19 vaccine

    Also known as: Pfizer-BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine

06

What researchers measure

Primary outcomes

  1. Change in SARS-CoV-2 IgG Titer Over Time

    Semi-quantitative SARS-CoV-2 IgG titer

    Time frame: 8 weeks (± 5 days) post-vaccination regimen completion; 24 weeks (± 5 days) post-vaccination regimen completion; and 52 weeks (± 5 days) post-vaccination regimen completion

Secondary outcomes

  1. Occurrence of post-vaccine reactions

    Subjective reporting of occurrence of post-vaccination reactions including anaphylactic reactions (such as difficulty breathing, swelling of face and throat, fast heartbeat, bad rash all over body, and dizziness and weakness); injection site pain; injection site swelling/hardness; injection site redness; tiredness; headache; muscle pain; chills; join pain; fever; nausea; feeling unwell; and/or swollen lymph nodes

    Time frame: Within 3 days after vaccine injections

  2. Severity of post-vaccine reactions

    Subjective reporting of severity of post-vaccine reactions (none, mild, moderate, or severe)

    Time frame: Within 3 days after vaccine injections

07

Study locations

1 site
  • Huntington Hospital
    Pasadena, California 91105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2022, 11 months.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 11 months is below that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Jun 11, 2021
StartActual
Mar 8, 2021
Primary completionActual
Mar 1, 2022
CompletionActual
Mar 1, 2022
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04922944
Lead sponsor
Huntington Memorial Hospital
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Mar 8, 2021
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Last update
Sep 19, 2024

Study contacts

Kimberly Shriner, MD
principal investigator · Huntington Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion